Behavioral Health of the Palm Beaches

Traffic police officers are frequently exposed to stress, anxiety, and depression, which adversely impact their health. This study hypothesized that these factors influence the hormonal, muscular, digestive, and cognitive systems of traffic police officers. The sample comprised 146 traffic police officers (42 women and 104 men) aged 30 to 38. Gender differences in symptoms were examined, and model fit was assessed using indicators such as chi-square, comparative fit index, root mean square error of approximation (RMSEA), and standardized root means residual (SRMR). Gender differences were observed, with women reporting more significant issues related to muscular (t = 2.77, p = .003), hormonal (t = 2.29, p = .001), and cognitive symptoms (t = 1.37, p = .08). The models demonstrated a good fit, particularly in the model examining digestive symptoms (CFI.95, RMSEA.06 (.05 -.08), SRMR.04). The findings indicate a substantial impact of stress, anxiety, and depression on traffic police officers' health. Psychological support and monitoring are recommended at traffic police stations. This research offers essential academic contributions by advancing understanding of the psychophysiological effects of stress, anxiety, and depression in high-stress occupations, using predictive modeling. Practically, the findings support the development of targeted mental health interventions and preventive strategies tailored to traffic police officers, contributing to improved occupational health and job performance.

INTRODUCTION: Medical waste can be reduced by utilizing the Neomedic Knotless Incontinence Mesh (KIM) sling with sterilizable, reusable trocars compared to those with disposable trocars. Our initial investigation of comparative effectiveness at 6 weeks was inconclusive. OBJECTIVE: To determine whether the KIM sling is noninferior to the TVT Exact sling at 1 year for treatment of stress urinary incontinence (SUI). METHODS: This was a single-center, randomized noninferiority trial comparing the outcomes of two retropubic slings, KIM vs TVT Exact, for treatment of SUI from August 2021 to June 2024. The primary outcome was effectiveness at 1 year defined by a composite outcome of a negative response to the question #17 on the PFDI-20 and no SUI retreatment. Secondary outcomes included rates of mesh exposure, urinary retention, and reoperation for mesh complications. For our sample size, we needed 72 per group based on a noninferiority margin of 14%, equal effectiveness of 90%, alpha 0.05, and 80% power with a 20% dropout. RESULTS: Among 147 participants, 73 (49.7%) were randomized to TVT Exact vs 74 (50.3%) to KIM. Baseline demographics were similar between the two groups; participants were predominantly older (58 for TVT Exact vs 59.7 for KIM, p=0.42), White (86.3% for TVT Exact vs 83.8% for KIM, p=0.67) nonsmokers (12.3% for TVT Exact vs 13.5% for KIM, p=0.83) with similar rates of stage III–IV prolapse (35.6% for TVT Exact vs 28.4% for KIM, p=0.30) and similar rates of prior hysterectomy (30.1% for TVT Exact vs 27.0% for KIM, p=0.68). There was a higher rate of concomitant anterior repair in the KIM group vs the TVT Exact group (38.4% for TVT Exact vs 56.8% for KIM, p=0.03). One-year validated questionnaires were completed by 138 (93%) participants, and 106 (72%) completed an in-person visit. Effectiveness at 1 year was 82.1% for the TVT Exact group vs 74.6% for the KIM group, with a risk difference of 7.4% (95% CI, −6.2, 21.1). Given that the 95% upper confidence limit was outside of the 14% noninferiority margin, noninferiority was unable to be demonstrated (Figure 1). For secondary outcomes, the rates of mesh exposure at 1 year were 11.1% (n=6) in the TVT Exact group vs 1.9% (n=1) in the KIM group (p=.11). Additional secondary outcomes are displayed in Table 1. CONCLUSIONS: The KIM sling is not noninferior to the TVT Exact sling for the treatment of SUI at 1 year based on a composite outcome score.

Twelve frameworks were milled from four polymeric materials (three per group): polyetheretherketone (PEEK), polyetherketoneketone (PEKK), poly(methyl methacrylate) (PMMA) and fibre-reinforced composite (FRC). Each framework was fitted with titanium links and screwed to implant analogues embedded in resin and tested for static load-bearing capacity up to 200N. Displacements were captured with two high-speed photographic cameras and analysed with a video correlation system on three spatial axes, U, V, and W, along with principal tensile, compressive and von Mises strains. PEEK exhibited the highest displacement, indicating greater flexibility, while FRC showed the lowest displacement, suggesting enhanced rigidity. Von Mises strain analysis revealed that PMMA and PEEK experienced higher strain, whereas PEKK and FRC demonstrated lower strain distribution. Bayesian ANOVA provided strong evidence for material differences. FRC exhibited superior load-bearing characteristics, reinforcing its potential as a viable clinical alternative to metal-based ISFPs.

Customized unicompartmental knee arthroplasty (C-UKA) utilizes implants manufactured on an individual patient basis, derived from pre-operative computed tomography images in an effort to more closely approximate the natural anatomy of the knee. The outcomes from 349 medial and lateral fixed-bearing C-UKA were reviewed. Implant survivorship analysis was conducted via retrospective chart review, and follow-up analysis was conducted via a single postoperative phone call or email. The rate of follow-up was 69% (242 knees). The average age at surgery was 71.1 years and the average body mass index was 28.8 kg/m2. Seven revision arthroplasties (2.1%) had knowingly been performed at an average of 1.9 years postoperatively (range: 0.1–3.9 years), resulting in an implant survivorship of 97.9% at an average follow-up of 4.2 years (range: 0.1–8.7) and 97.9% at an average of 4.8 years (range: 2.0–8.7) when knees with less than two years of follow-up were excluded. The reasons for revision were implant loosening (one knee), infection (two knees), progression of osteoarthritis (two knees), and unknown reasons (two knees). The average KOOS, JR. interval score was 84 (SD: 14.4). Of those able to be contacted for follow-up analysis, 67% were “very satisfied,” 26% were “satisfied,” 4% were “neutral,” 2% were “dissatisfied,” and 1% were “very dissatisfied.” When asked if the knee felt “natural,” 60% responded with “always,” 35% responded with “sometimes,” and 5% responded with “never.” After analyzing a large cohort of C-UKA, we found favorable rates of survivorship, satisfaction, and patient-reported functional outcomes.

Yttrium-90 microsphere radioembolization with (90)Y microspheres is a locoregional radiation therapy employed for unresectable hepatic neoplasms by permanently implanting (90)Y-containing microspheres into tumors via the hepatic artery. Non-target delivery of (90)Y microspheres can result in gastrointestinal (GI) symptoms. We present the case of a woman with ischemic gastropathy as a result of Y-90 therapy targeted for hepatic metastasis from invasive ductal carcinoma of the breast. This is a 64 year-old female with breast cancer with isolated hepatic metastasis. As a result, she underwent chemoembolization of this hepatic lesion. Days later she developed left upper quadrant ( LUQ ) abdominal pain associated with nausea and vomiting. Several days of empiric proton-pump inhibitors ( PPIs ) and antiemetics offered no benefit. As a result, an upper endoscopy was performed. Endoscopy demonstrated a large wedged shaped area of severe gastric erythema and ulceration extending from the cardia esophageal junction to the incisura with linear margins. The temporal relationship of the Y90 radioembolization coupled with the endoscopic findings were suggestive of ischemic gastropathy. Pathology confirmed results ulcerated gastric mucosa with basophilic beads in vascular spaces, consistent with Y-90 radioembolization beads. Immunohistochemistry was negative for H. pylori. These findings suggest gastropathy due to radioembolization. Radioembolization using yttrium-90 microspheres (Y-RE) is a novel modality of treatment for breast cancer liver metastases (BCLM) patients in whom other locoregional and systemic treatment options have failed. The etiology of persistent gastric ulcerations in patients presenting months after radioembolization treatment remains unclear. Postradioembolization syndrome, including fatigue, abdominal pain, nausea, vomiting, anorexia, or fever is fairly common and is seen in upto 70 % patients undergoing radioembolization. Diffusion-weighted magnetic resonance imaging is superior to PET/CT in assessing treatment response and can be used to guide further management in these patients. Patients with left lobe tumors adjacent to the stomach do not exhibit radiation effects following radioembolization. Studies have shown Y-RE to be a safe and effective treatment option for BCLM patients and for those with hepatic metastasis from colorectal cancer. Studies investigating the use of Y-RE combined with systemic therapy are required.

This is a case of a 45 y/o male with a history of GERD, hemorrhoids and syphilis who presented for 2 months of anal pain, hematochezia and constipation, ultimately diagnosed with proctitis. This is being presented given the unique etiology of proctitis, rare in clinical practice. While findings including endoscopy present similarly to IBD, this diagnosis requires a high degree of suspicion and supportive history. He previously failed fiber, probiotics and stool softeners. He admitted to anal intercourse but denied a family history of colon polyps or cancer. Exam was notable for hemorrhoids, perianal condylomata and anal fissure. Labs were normal and no imaging was performed. Given his symptoms, he underwent diagnostic colonoscopy with good prep to the terminal. Nodular, friable and ulcerated mucosa encompassing 50% of the luminal circumference, extending 10cm proximal to the anus was seen. Pending biopsy results, he was started on empiric rectal mesalamine. Pathology revealed acute cryptitis, chronic inflammation, granulation tissue and reactive changes. Findings were not classic of IBD given inflammation was not circumferential and was more mass like than ulcerative. Biopsy was negative for CMV, HSV 1/2, spirochetes and dysplasia or malignancy using pancytokeratin and p16 immunostains. Serum HIV and syphilis were negative. Given atypical appearance, rectal swab was obtained, revealing C. trachomatis and N. gonorrhoeae RNA. These findings and clinical suspicion led to a diagnosis of Lymphogranuloma venereum proctitis with a 21 days of treatment with doxycycline. This is an uncommon form of infectious proctitis caused by the L1-L3 serovars of Chlamydia trachomatis. Risk factors include men who have sex with men, previous STIs and ulcerative disease. Lymphatic spread occurs after the bacterium passes the epithelial barrier, usually via unprotected anal intercourse. Hemorrhagic proctitis results with anorectal pain, bleeding, tenesmus and constipation. Endoscopically there is rectal inflammation, often mistaken for IBD. Clues include supportive history and failure to improve with IBD therapy. Diagnostic techniques include nucleic acid amplification testing to detect C. trachomatis and the specific serotype. Alternatives include culture and serology. First line therapy is doxycycline with erythromycin preferred in pregnant or breastfeeding women. As with other STIs, sexual partners should be informed, screened and treated if similarly affected.1526_A Figure 1. Endoscopic view from colonoscopy. Evidence of nodular appearing, mass like ulceration of the rectal mucosa, encompassing approximately fifty percent of the luminal circumference.1526_B Figure 2. Histologic slide from rectal biopsy, detailing acute cryptitis with associated reactive changes.1526_C Figure 3. Magnification of histologic slide from rectal biopsy, showing further evidence of chronic inflammation alongside acute cryptitis.

ABSTRACTDysthymia affects millions of people and has been associated with impaired psychosocial and occupational functioning and poor clinical treatment outcomes. Yet few studies have examined protective factors that can be utilized to help individuals with dysthymia in clinical settings, particularly among individuals with comorbid substance use disorders. The purpose of this study was to examine the potential protective quality of adult attachment dimensions, spirituality, and meaning in life among clients with and without dysthymia in treatment for addiction. Data were obtained from 305 self-report questionnaires administered to clients attending a residential substance abuse treatment center. Approximately 25% of the sample met criteria for dysthymia. Results from logistic regression analyses indicated that purpose and meaning in life and attachment anxiety were the most important protective factors against having dysthymia. These results suggest that mental health professionals may need to integrate these protective factors into the treatment of individuals with dysthymia and substance use disorders, which may enhance treatment outcomes and maximize treatment effectiveness. Future studies should continue to explore protective factors that can assist individuals who experience these comorbid conditions and consider replicating this study using an ethnically diverse sample and other clinical settings to determine the generalizability of the findings.

The clinical practice of neurology generates an enormous amount of data. Current data entry tools and reporting requirements are inefficient and frustrating. This comprehensive review of data collection in multiple domains of clinical practice includes billing and payment requirements, electronic health record documentation requirements, quality measurements, public reporting, and the evolution of clinical decision support. Quality measurements are increasingly affecting patient care and physician reimbursement. By understanding current data collection and by using appropriate tools, neurologists can begin to reduce the burden of data collection and ensure maximum reimbursement. The American Academy of Neurology's Axon registry is the next step in the evolution of clinical data collection and will begin to empower every neurologist to succeed in the shifting landscape of health care and physician payment reform.